ID: hyp-sda-2026-04-01-001-2
Hypothesis
Multi-Target Microglial Metabolic Reprogramming
Combinatorial targeting of TREM2, APOE, and CLU network with metabolic reprogramming toward anti-inflammatory microglial phenotypes.
EvidencePending (0%)📖 5 cit🗣 1 debates✓ 5 support✗ 1 oppose
✓ All Quality Gates Passed
🧪 Overview
Combinatorial targeting of TREM2, APOE, and CLU network with metabolic reprogramming toward anti-inflammatory microglial phenotypes
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["Microglial Dysfunction<br/>AD Neuroinflammation"]
B["TREM2 Signaling Activation<br/>Lipid Phagocytosis Enhancement"]
C["APOE Modulation<br/>Cholesterol Efflux Optimization"]
D["CLU Clusterin Activity<br/>Amyloid Chaperone and Clearance"]
E["Combinatorial Network Targeting<br/>TREM2 plus APOE plus CLU"]
F["Metabolic Reprogramming<br/>Anti-Inflammatory Microglial Phenotype"]
G["Amyloid and Lipid Burden Cleared<br/>Neuroinflammation Resolved"]
H["Neuroprotective Microglial State<br/>AD Progression Slowed"]
A --> B
A --> C
A --> D
B --> E
C --> E
D --> E
E --> F
F --> G
G --> H
style E fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style H fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7⚖️ Evidence
⚖️ Evidence Matrix5 supports0 contradicts
Supports
The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases.
Supports
TREM2 drives microglia response to amyloid-β via SYK-dependent and -independent pathways.
Supports
A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease.
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — ['TREM2'
No curated PDB or AlphaFold mapping for ['TREM2' yet. Search RCSB →
💉 Clinical Trials (5)
0
Active
Active
0
Completed
Completed
0
Total Enrolled
Total Enrolled
PHASE1
Highest Phase
Highest Phase
UNKNOWN·NCT05419596 · Istanbul University
Cognitive Dysfunction
Urologic Surgery
COMPLETED·NCT06224920 · Ludwig-Maximilians - University of Munich
Alzheimer Disease Corticobasal Syndrome
magnetic resonance imaging electroencephalography blood and CSF biomarker
RECRUITING·NCT06274528 · Washington University School of Medicine
Alzheimer Disease
Lemborexant 10 mg Lemborexant 20mg Placebo
COMPLETED·NCT04388254 · Cassava Sciences, Inc.
Alzheimer Disease
Simufilam 100 mg oral tablet Placebo
COMPLETED·NCT04570644 · AZTherapies, Inc.
Healthy Volunteers Alzheimer Disease
ALZT-OP1 (cromolyn and ibuprofen) ALZT-OP1a (cromolyn) and ALZT-OP1b (ibuprofen)
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for ['TREM2', 'APOE', 'CLU'].
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
High
0.0580
Events (7d)
1
Price History
▼8.2%💾 Resource Usage
LLM Tokens
14,692
$0.0882
Total Cost
$0.0882
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF RNA-seq and metabolomics are performed on sorted CD11b+CD45+ microglia from post-mortem prefrontal cortex of AD cases with TREM2-R47H variants (n=30), APOE4/4 homozygotes (n=30), and CLU-rs11136000 | Microglial transcriptomic and metabolomic signatures in carriers of TREM2, APOE4, and CLU risk variants will show a pro-glycolytic, anti-oxidative metabolic pro | — no observation — | pending | 0.60 |
| IF 5xFAD mice receive combined TREM2 agonism (biweekly anti-TREM2 antibody, 2 mg/kg), APOE4-neutralization (CRISPRi-lentivirus in hippocampus), and CLU silencing (ASO, 50 μg/kg/week) plus NAD+ repleti | Triple-target + metabolic reprogramming will reduce amyloid plaque area by ≥40% (stereology), increase microglia branching complexity (Iba1 Sholl analysis), and | — no observation — | pending | 0.55 |
🔮 Falsifiable Predictions (2)
pendingconf 60%
IF RNA-seq and metabolomics are performed on sorted CD11b+CD45+ microglia from post-mortem prefrontal cortex of AD cases with TREM2-R47H variants (n=30), APOE4/4 homozygotes (n=30), and CLU-rs11136000 risk carriers (n=30) matched for age/PMI/Braak stage, THEN risk allele carriers will show elevated
Predicted outcome: Microglial transcriptomic and metabolomic signatures in carriers of TREM2, APOE4, and CLU risk variants will show a pro-glycolytic, anti-oxidative met
Falsification: No significant difference in glycolytic vs. oxidative phosphorylation metabolites between risk carriers and non-carriers (p>0.05, ANOVA with Bonferroni correction) OR HIF1α target genes show equal or
pendingconf 55%
IF 5xFAD mice receive combined TREM2 agonism (biweekly anti-TREM2 antibody, 2 mg/kg), APOE4-neutralization (CRISPRi-lentivirus in hippocampus), and CLU silencing (ASO, 50 μg/kg/week) plus NAD+ repletion (nicotinamide riboside 400 mg/kg diet) from 3-4 months of age for 12 weeks, THEN amyloid plaque b
Predicted outcome: Triple-target + metabolic reprogramming will reduce amyloid plaque area by ≥40% (stereology), increase microglia branching complexity (Iba1 Sholl anal
Falsification: Plaque burden does not decrease by ≥40% OR microglia remain dystrophic (ramified endpoints <10 Sholl intersections) OR spatial memory shows no improvement (escape latency >35 seconds) despite confirme
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesis
| source | v1_phase_c_backfill |
| origin_type | debate_synthesis |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.